CHRN
ChronoScale Corporation
There isn't enough reported data to score CHRN yet.
NVDA
NVIDIA Corporation
NVDA's fundamentals are strong and it looks cheap: trading at 21x earnings, about a third of its usual 65x. Analysts expect strong earnings growth.
CHRN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CHRN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
CHRN PE Valuation
CHRN has no meaningful PE right now: it lost money over the past year.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
CHRN Forward outlook
There aren't enough analyst estimates for CHRN to show an outlook.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
CHRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$6.83 | +$0.40 |
| Q4 2025 | -$6.59 | +$1.84 |
| Q3 2025 | -$5.56 | +$4.19 |
| Q2 2025 | -$6.52 | +$5.33 |
| Q1 2025 | -$7.23 | +$7.32 |
| Q4 2024 | -$8.43 | +$8.07 |
| Q3 2024 | -$9.75 | +$7.05 |
| Q2 2024 | -$11.85 | +$6.30 |
CHRN is still losing money, but far less than before: $6.83 per share over the past year, against $47.25 at its worst in late 2019.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over CHRN on earnings quality, reporting a profit while its opponent remains loss making.
CHRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $41.5M | +881% |
| Q1 2026 | $2.1M | -37% |
| Q4 2025 | $3.1M | -38% |
| Q3 2025 | $4.2M | +2.4% |
| Q2 2025 | $2.1M | -58% |
| Q1 2025 | $3.4M | -10% |
| Q4 2024 | $5.1M | +5% |
| Q3 2024 | $4.1M | -10% |
CHRN's revenue is growing: $41M last quarter, up 1917% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -60% | +133 points |
| Q1 2026 | -262% | -161 points |
| Q4 2025 | -144% | -100 points |
| Q3 2025 | -33% | +31 points |
| Q2 2025 | -193% | -146 points |
| Q1 2025 | -102% | -15 points |
| Q4 2024 | -44% | +27 points |
| Q3 2024 | -64% | -0.3 points |
CHRN's operating margin was −60% last quarter, up 133 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over CHRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over CHRN on profitability, with a higher operating margin.
CHRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +$13.6M |
| Q1 2026 | -$2.1M | -$148K |
| Q4 2025 | -$4.5M | -$3M |
| Q3 2025 | -$2.1M | +$212K |
| Q2 2025 | -$3.5M | -$814K |
| Q1 2025 | -$2M | +$1.5M |
| Q4 2024 | -$1.5M | +$173K |
| Q3 2024 | -$2.3M | +$1.1M |
CHRN's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over CHRN on cash flow, with more consistent year-over-year improvement.
CHRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3981% | +142M shares |
| 1 year | +8489% | +144M shares |
| 3 years | +16727% | +145M shares |
| 5 years | +34737% | +145M shares |
CHRN has 145M diluted shares, up 8489% from a year ago.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has the edge over CHRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
CHRN Net Leverage
CHRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CHRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.3 | Neutral |
| Stochastic | 8.3 | Oversold |
CHRN's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
CHRN PE vs Technology Sector
CHRN has no meaningful PE right now: it lost money over the past year.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
CHRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.4 | 30% below |
| 20 week MA | $18.8 | 42% below |
| 50 week MA | $14.5 | 25% below |
| 100 week MA | $10.1 | 7.5% above |
| 200 week MA | $14.9 | 27% below |
CHRN's trend is mixed: it's above one of its five weekly moving averages, and 27% below its 200-week average.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
CHRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $78.8 | $104.7 | +33% |
| 2021 | $104.7 | $45.3 | -57% |
| 2022 | $45.3 | $18.6 | -59% |
| 2023 | $18.6 | $37.5 | +102% |
| 2024 | $37.5 | $9.74 | -74% |
| 2025 | $9.74 | $5.56 | -43% |
| 2026 YTD | $5.56 | $10.9 | +95% |
CHRN has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.